Results 11 to 20 of about 659,528 (297)

A brief history of and future prospects for pneumococcal vaccination in Malaysia

Pneumonia, 2023
Pneumococcal pneumonia remains a significant global public health issue. Malaysia has recently added the 10 valent pneumococcal conjugate vaccine to its national immunisation programme.
Alex J. J. Lister, Evelin Dombay, David W. Cleary, Lokman H. Sulaiman, Stuart C. Clarke   +4 more
doaj   +1 more source

Pneumococcal vaccine [PDF]

Postgraduate Medical Journal, 1997
Summary Streptococcus pneumoniae is a frequent cause of pneumonia and meningitis. This article looks at the pneumococcal vaccine, its uses, efficacy, and adverse effects and how vaccination may be improved. We also look at the role of the new conjugate vaccines.
K L, Hattotuwa, C R, Hind
openaire   +2 more sources

Pivotal Phase 3 Randomized Clinical Trial of the Safety, Tolerability, and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged ≥18 Years

Clinical Infectious Diseases, 2021
Background Pneumococcal conjugate vaccines (PCVs) have significantly reduced pneumococcal disease, but disease from non-PCV serotypes remains. The safety, tolerability, and immunogenicity of a 20-valent PCV (PCV20) were evaluated.
B. Essink, Charu Sabharwal, Kevin P. Cannon, R. Frenck, Himal Lal, Xia Xu, V. Sundaraiyer, Yahong Peng, Lisa Moyer, M. Pride, Ingrid L Scully, K. Jansen, W. Gruber, D. Scott, W. Watson   +14 more
semanticscholar   +1 more source

Evolution of pneumococcal serotype epidemiology in Botswana following introduction of 13-valent pneumococcal conjugate vaccine

PLoS ONE, 2022
Pneumococcal conjugate vaccines reduce the burden of invasive pneumococcal disease, but the sustained effect of these vaccines can be diminished by an increase in disease caused by non-vaccine serotypes.
Sweta M. Patel, Yazdani B. Shaik-Dasthagirisaheb, Morgan Congdon, Rebecca R. Young, Mohamed Z. Patel, Tiny Mazhani, Sefelani Boiditswe, Tirayaone Leburu, Kwana Lechiile, Tonya Arscott-Mills, Andrew P. Steenhoff, Kristen A. Feemster, Samir S. Shah, Coleen K. Cunningham, Stephen I. Pelton, Matthew S. Kelly   +15 more
doaj   +3 more sources

Epidemiology of non-vaccine serotypes of Streptococcus pneumoniae before and after universal administration of pneumococcal conjugate vaccines

Human Vaccines & Immunotherapeutics, 2021
The universal administration of pneumococcal conjugate vaccines (PCVs) had been demonstrated as an effective way to prevent Streptococcus pneumoniae infection.
Qian-qian Du, W. Shi, Dan Yu, K. Yao
semanticscholar   +1 more source

Older adults' vaccine hesitancy: Psychosocial factors associated with influenza, pneumococcal, and shingles vaccine uptake.

Vaccine, 2020
Influenza, pneumococcal disease, and shingles (herpes zoster) are more prevalent in older people. These illnesses are preventable via vaccination, but uptake is low and decreasing.
L. B. Nicholls, A. Gallant, N. Cogan, S. Rasmussen, D. Young, L. Williams   +5 more
semanticscholar   +1 more source

Pneumococcal Conjugate Vaccination Followed by Pneumococcal Polysaccharide Vaccination in Lung Transplant Candidates and Recipients

Transplantation Direct, 2020
Background. Pneumococcal conjugate vaccination as well as pneumococcal polysaccharide vaccination are recommended for lung transplant candidates and recipients, but the combination of these vaccines has not been extensively studied in these specific ...
Thijs W. Hoffman, MD, Bob Meek, PhD, Ger T. Rijkers, PhD, Jan C. Grutters, MD, PhD, Diana A. van Kessel, MD, PhD   +4 more
doaj   +1 more source

Distribution and Variation of Serotypes and Pneumococcal Surface Protein A Clades of Streptococcus pneumoniae Strains Isolated From Adult Patients With Invasive Pneumococcal Disease in Japan

Frontiers in Cellular and Infection Microbiology, 2021
Pneumococcal surface protein A (PspA) is a surface protein of Streptococcus pneumoniae that may be a candidate antigen for new pneumococcal vaccines.
Bin Chang, Yuki Kinjo, Yuki Kinjo, Yuki Kinjo, Masatomo Morita, Kosuke Tamura, Hiroshi Watanabe, Yoshinari Tanabe, Koji Kuronuma, Jiro Fujita, Kengo Oshima, Takaya Maruyama, Shuichi Abe, Kei Kasahara, Junichiro Nishi, Tetsuya Kubota, Makoto Ohnishi, Shigeru Suga, Kazunori Oishi   +18 more
doaj   +1 more source

Pneumococcal Vaccines

Microbiology Spectrum, 2014
ABSTRACTStreptococcus pneumoniaeis a Gram-Positive pathogen that is a major causative agent of pneumonia, otitis media, sepsis and meningitis across the world. The World Health Organization estimates that globally over 500,000 children are killed each year by this pathogen. Vaccines offer the best protection againstS. pneumoniaeinfections.
D. E. Briles, J. C. Paton, R. Mukerji, E. Swiatlo, M. J. Crain   +4 more
openaire   +4 more sources

An economic analysis of a pneumococcal vaccine programme in people aged over 64 years in a developed country setting. [PDF]

, 2005
BACKGROUND: Polysaccharide pneumococcal vaccination for older adults is being introduced in developed country settings. Evidence of protection by this vaccine against pneumococcal pneumonia, or confirmation that illness and death from bacteraemia are ...
Cutts, Felicity T, Hall, Andrew J, Mangtani, Punam, Roberts, Jennifer A   +3 more
core   +1 more source